Document is current
Any future updates will be listed below
-
Authors
Eschen, Jens Toft
Jensen, Line Louise
Hausmann, David
Lind, Allice Nyborg Rosenkrans
Lukacova, Slavka
Weischenfeldt, Joachim
Lassen, Ulrik
Westphal, Manfred
Winkler, Frank
Simonsen, Ulf
Korshoej, Anders Rosendal
-
Funding
Funding for this research was provided by:
Danmarks Frie Forskningsfond (4308-00118B9)
Novo Nordisk Fonden (NNF24OC0095318)
- License Information
-
More Information
Article History
Received: 25 November 2025
Accepted: 19 February 2026
First Online: 14 April 2026
Declarations
:
: The study has been approved by the Danish Medicines Agency ( Lægemiddelstyrelsen ) and by the National Committee on Health Research Ethics ( De Videnskabsetiske Medicinske Komitéer ) (EU-CT: 2025–522605-37–00, authorized 14 October 2025). The trial will be conducted in accordance with the principles of the Declaration of Helsinki, the ICH-GCP guidelines, and all applicable Danish and European legislation. Written informed consent will be obtained from all participants before any trial-related activities by a qualified study team member. It may be withdrawn at any time without consequences for subsequent clinical care in accordance with Danish legislation. The Danish Patient Compensation Association will cover all patient injuries.
: Not applicable.
: The authors declare no competing interests.
